Since joining Versant in 2011, Jerel has been involved in launching and investing in a number of Versant’s portfolio companies including BlueRock (sale), Crispr (public 2016), Inception 4 (sale), Inception 5 (sale), Quanticel (sale), Akero (2019 IPO), Northern (sale), Repare (2020 IPO), Chinook (2020 reverse merger), Graphite Bio (2021 IPO), Turnstone, Ventus, Rayze and Tentarix. He has focused on company creation, syndicated deals, and creative corporate transactions. He was also instrumental in establishing Versant’s presence in Canada. Jerel was promoted to Managing Director at Versant in December 2015.
Location
Canada
Notable investments
No items found.
Check size range(s)
$0 - $100K
$100K - $500K
$500K - $1M
$1M - $3M
$3M - $10M
Rounds their fund invests in
Series A
Rounds their fund leads
No items found.
Sectors their fund invests in
Biotech
Geographies their fund invests in
USA
Canada
Europe
Browse through a massive startup database
Browse Harmonic, our favorite resource for parsing through the world's startup data.
Partner
Learn more about Harmonic
No items found.
No colleagues here yet.
Funds they're a part of
Versant Ventures
About the Fund
Provides state-of-the-art laboratories to launch novel biotech companies with academic founders.
View Profile
Their Colleagues
Sheets Their fund(s) are in
Is this you? Have any edits?
Fill out our update request form and we'll update ASAP
Related Investors
Round-focused Sheets
Geography-focused Sheets
Sector-focused Sheets
